NCT00879086 2023-06-22
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer
Eisai Inc.
Phase 2 Completed
Clinical Trials
26 trialsNCT02915744 2023-04-14
ATTAIN
Nektar Therapeutics
Phase 3 Completed
NCT00080301 2020-11-02
Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
R-Pharm
Phase 3 Completed
NCT00082433 2020-11-02
Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
R-Pharm
Phase 3 Completed
NCT00162136 2020-11-02
Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.
R-Pharm
Phase 1 Completed
NCT00832117 2020-10-28
Phase I Combination Ixabepilone + Cisplatin
R-Pharm
Phase 1 Completed
NCT00983801 2020-10-28
Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer
R-Pharm
Phase 2 Completed
NCT01416389 2019-09-18
A Study of LY2523355 in Participants With Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00004927 2017-01-30
BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
R-Pharm
Phase 1 Completed
NCT00080262 2017-01-30
Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)
R-Pharm
Phase 2 Completed
NCT00207129 2017-01-30
Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies
R-Pharm
Phase 1 Completed
NCT00309049 2017-01-30
Ixabepilone Administered as an Enteric Coated Formulation.
R-Pharm
Phase 1/2 Completed
NCT01018966 2017-01-30
Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors
R-Pharm
Phase 1 Completed
NCT01027208 2017-01-30
A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline
R-Pharm
Phase 2 Completed
NCT01075100 2016-12-07
Ixabepilone + Carboplatin Metastatic Breast Cancer
US Oncology Research
Phase 2 Completed
NCT00362830 2016-09-19
A Study of the Alternative Administration of Ixabepilone and Vinflunine
Bristol-Myers Squibb
Phase 1 Completed
NCT00322374 2016-03-10
Phase I Combination w/ Epirubicin
R-Pharm
Phase 1 Completed
NCT00370552 2016-03-10
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
R-Pharm
Phase 2 Completed
NCT00383149 2016-03-10
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
R-Pharm
Phase 2 Completed
NCT00422097 2016-03-10
A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer
R-Pharm
Phase 1 Completed
NCT00490646 2016-03-10
A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer
R-Pharm
Phase 2 Completed
NCT00568022 2016-03-10
A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer
R-Pharm
Phase 1 Completed
NCT00593827 2016-03-10
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
R-Pharm
Phase 2 Completed
NCT00633464 2016-03-10
Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer
R-Pharm
Phase 2 Completed
NCT00455533 2016-02-24
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT00798252 2015-07-07
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
Bristol-Myers Squibb
Phase 1 Completed